|
Patient
|
Sex
|
Disease duration (months)
|
Muscle weakness
|
DM skin rash
|
Serum CPKa (U/l)
|
EMGb
|
ANA (IF)b
|
Specific autoantibodies
|
Muscle biopsyc
|
|---|
| | | | | | | | | |
Inflammation (site of biopsy)
|
Immunoreactivity for
|
|---|
| | | | | | | | | | |
MHC-I
|
εMy (% of total)
|
|---|
|
Group I
| | | | | | | | | | | |
|---|
|
1
|
F
|
4
|
P
|
A
|
5027
|
+
|
-
|
Jo-1, RoSSA
|
++ (VL)
|
++
|
36.60
|
|
2
|
F
|
15
|
P
|
A
|
8570
|
+
|
-
|
Jo-1
|
++ (D)
|
++
|
35.50
|
|
3
|
F
|
8
|
P
|
A
|
2762
|
-
|
+
|
Jo-1, RoSSA
|
++ (VL)
|
+
|
15.50
|
|
4
|
F
|
168
|
P
|
A
|
1100
|
+
|
-
|
-
|
++ (VL)
|
++
|
1.09
|
|
5
|
M
|
29
|
P
|
A
|
1125
|
-
|
+
|
Mi-2
|
++ (VL)
|
+
|
0.33
|
|
6
|
F
|
13
|
P
|
P
|
292
|
+
|
-
|
-
|
++ (VL)
|
++
|
0
|
|
7
|
F
|
3
|
P
|
A
|
6705
|
+
|
-
|
Jo-1
|
+ (VL)
|
+
|
7.79
|
|
8
|
F
|
25
|
A
|
A
|
1840
|
+
|
+
|
tRNA, RoSSA
|
+ (VL)
|
++
|
2.00
|
|
9
|
M
|
25
|
P
|
P
|
484
|
+
|
-
|
Mi-2
|
+ (D)
|
++
|
6.00
|
|
10
|
M
|
79
|
P
|
A
|
535
|
-
|
+
|
U1RNP, RoSSA
|
+ (VL)
|
++
|
36.60
|
|
11
|
F
|
9
|
P
|
A
|
2762
|
+
|
+
|
-
|
+ (VL)
|
+
|
15.55
|
|
12
|
F
|
13
|
P
|
A
|
666
|
+
|
-
|
-
|
+ (TA)
|
++
|
3.10
|
|
13
|
M
|
36
|
P
|
A
|
2580
|
-
|
+
|
tRNA
|
+ (VL)
|
+
|
0.20
|
|
14
|
F
|
103
|
P
|
A
|
893
|
+
|
+
|
Jo-1
|
+ (VL)
|
+
|
0.06
|
|
Group II
| | | | | | | | | | | |
|
15
|
F
|
27
|
P
|
A
|
173
|
-
|
+
|
Jo-1
|
- (VL)
|
+
|
0.13
|
|
16
|
M
|
72
|
P
|
A
|
548
|
-
|
-
|
-
|
- (VL)
|
+
|
0
|
|
17
|
F
|
79
|
P
|
A
|
< 160
|
-
|
+
|
Ro/SSA
|
- (D)
|
++
|
0
|
|
18
|
M
|
33
|
P
|
P
|
600
|
ND
|
+
|
-
|
- (D)
|
++
|
0.42
|
|
19
|
F
|
21
|
P
|
A
|
221
|
+
|
+
|
Scl70, Ku
|
- (VL)
|
++
|
2.60
|
|
20
|
F
|
180
|
P
|
A
|
1157
|
+
|
+
|
Jo-1
|
- (VL)
|
+
|
0
|
|
21
|
F
|
67
|
P
|
A
|
533
|
+
|
+
|
Mitotic apparatus
|
- (D)
|
+
|
1.1
|
|
Group III
| | | | | | | | | | | |
|
22
|
F
|
237
|
P
|
A
|
450
|
-
|
-
|
-
|
- (VL)
|
-
|
0.50
|
|
23
|
F
|
58
|
P
|
A
|
43
|
+
|
-
|
-
|
- (VL)
|
-
|
0
|
|
24
|
F
|
237
|
P
|
A
|
742
|
+
|
-
|
-
|
- (D)
|
-
|
0
|
|
25
|
M
|
24
|
P
|
A
|
250
|
-
|
-
|
-
|
- (VL)
|
-
|
0
|
|
26
|
F
|
15
|
P
|
A
|
1600
|
-
|
-
|
-
|
- (VL)
|
-
|
1.11
|
|
27
|
F
|
68
|
P
|
A
|
628
|
+
|
-
|
-
|
- (VL)
|
-
|
0
|
|
28
|
M
|
33
|
P
|
P
|
9868
|
+
|
-
|
-
|
- (VL)
|
-
|
0
|
|
29
|
F
|
24
|
P
|
P
|
254
|
-
|
+
|
-
|
- (VL)
|
-
|
0
|
- aValues correspond to those obtained at the time of muscle biopsy. b+ and -, presence and absence of positive response, respectively. c+ and ++, degree of inflammation and MHC-I immunofluorescence, evaluated as described in Materials and methods; -, absence. DM, dermatomyositis; CPK, creatine phosphokinase; EMG, electromyography; ANA (IF), antinuclear antibodies (immunofluorescence); MHC-I: class I major histocompatibility complex antigen; εMy (% of total), percentage of myofibers positive for embryonic skeletal myosin on total biopsy fibers; F, female; M, male; P, present; A, absent; VL, vastus lateralis muscle; D, deltoid muscle; TA, tibialis anterior muscle; ND, not done.
